Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Meth...Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Methods:Patients were treated with nab-paclitaxel at a dose of 125 mg/m2 on day 1 and 8,and S-1,80 to 120 mg/day on days 1-14 of a 21-day cycle.Treatments were repeated until disease progression or unacceptable toxicity occurred.The primary endpoint was objective response rate(ORR).The secondary endpoints were median progression-free survival(PFS),overall survival(OS),and adverse events(AEs).Results:The number of patients enrolled were 54,and 51 patients were evaluated for efficacy.A total of 14 patients achieved partial response(PR)with an ORR of 27.5%.The ORR varied by sites,with 53.8%(7/13)for gallbladder carcinoma,18.4%(7/38)for cholangiocarcinoma.The most common grade 3 or 4 toxicities were neutropenia and stomatitis.The median PFS and OS were 6.0 and 13.2 months,respectively.Conclusions:The combination of nab-paclitaxel with S-1 showed explicit antitumor activities and favorable safety profile in advanced BTC and could serve as a potential non-platinum and-gemcitabine-based regimen.展开更多
目的:探讨替吉奥单药对胃癌中幽门螺杆菌(H.pylori,Hp)的感染及球状C1q受体基因(gC1qR)表达的影响。方法:以胃癌、胃炎病例组织及胃癌细胞系为研究对象,采用实时定量聚合酶链反应(Real time PCR)检测gC1qR m RNA表达水平;采用Hp DNA PC...目的:探讨替吉奥单药对胃癌中幽门螺杆菌(H.pylori,Hp)的感染及球状C1q受体基因(gC1qR)表达的影响。方法:以胃癌、胃炎病例组织及胃癌细胞系为研究对象,采用实时定量聚合酶链反应(Real time PCR)检测gC1qR m RNA表达水平;采用Hp DNA PCR方法,对胃窦部组织标本进行Hp水平检测;流式细胞技术进行细胞凋亡的检测及transwell实验进行细胞侵袭能力的检测。结果:在40对配对组织中有33对肿瘤组织gC1qR m RNA表达低于配对的胃炎病例组织;替吉奥单药可诱导gC1qR基因表达,抑制胃癌细胞Hp感染,同时增加胃癌细胞的凋亡率及降低胃癌细胞侵袭能力。结论:替吉奥单药诱导gC1qR基因表达,影响Hp对胃癌发生发展,是治疗胃癌的首选药物。展开更多
目的:研究程序性死亡蛋白-1(programmed death protein-1,PD-1)抑制剂(信迪利单抗)联合TS方案(紫杉醇+替吉奥)治疗进展期胃癌腹膜腔转移患者的临床效果及安全性。方法:回顾性分析2019年8月—2021年12月本院收治的80例进展期胃癌腹膜腔...目的:研究程序性死亡蛋白-1(programmed death protein-1,PD-1)抑制剂(信迪利单抗)联合TS方案(紫杉醇+替吉奥)治疗进展期胃癌腹膜腔转移患者的临床效果及安全性。方法:回顾性分析2019年8月—2021年12月本院收治的80例进展期胃癌腹膜腔转移患者的临床资料,将其根据治疗方式分为对照组和观察组,每组各40例。对照组采用TS方案治疗,观察组患者在对照组的基础上再给予PD-1抑制剂治疗。比较两组患者的临床疗效、治疗前后肿瘤标志物[糖类抗原(CA199)、癌胚抗原(CEA)]水平。观察治疗前、治疗1、2个疗程后的病灶直径水平,对比两组患者治疗期间的不良反应发生情况。治疗结束后对两组患者随访1年,观察随访期间的生存情况。结果:观察组总有效率高于对照组(87.50%vs 65.00%,P<0.05)。治疗后,两组患者的血清CA199、CEA水平均低于治疗前(P<0.05),且观察组患者的血清CA199、CEA水平低于对照组(P<0.05)。与治疗前比较,治疗1、2个疗程后两组患者的病灶直径水平均降低(P<0.05),观察组患者治疗1、2个疗程后病灶直径水平低于对照组(P<0.05)。观察组患者的胃肠道反应、白细胞减少、贫血、甲状腺功能减退、手足综合征等不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。观察组患者的生存率高于对照组(55.00%vs 30.00%,P=0.024)。结论:PD-1抑制剂联合TS方案可明显提高进展期胃癌腹膜腔转移患者的临床疗效,下调肿瘤标志物水平,缩小病灶,更有利于提高的患者生存率且安全性佳。展开更多
文摘Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Methods:Patients were treated with nab-paclitaxel at a dose of 125 mg/m2 on day 1 and 8,and S-1,80 to 120 mg/day on days 1-14 of a 21-day cycle.Treatments were repeated until disease progression or unacceptable toxicity occurred.The primary endpoint was objective response rate(ORR).The secondary endpoints were median progression-free survival(PFS),overall survival(OS),and adverse events(AEs).Results:The number of patients enrolled were 54,and 51 patients were evaluated for efficacy.A total of 14 patients achieved partial response(PR)with an ORR of 27.5%.The ORR varied by sites,with 53.8%(7/13)for gallbladder carcinoma,18.4%(7/38)for cholangiocarcinoma.The most common grade 3 or 4 toxicities were neutropenia and stomatitis.The median PFS and OS were 6.0 and 13.2 months,respectively.Conclusions:The combination of nab-paclitaxel with S-1 showed explicit antitumor activities and favorable safety profile in advanced BTC and could serve as a potential non-platinum and-gemcitabine-based regimen.
文摘目的:探讨替吉奥单药对胃癌中幽门螺杆菌(H.pylori,Hp)的感染及球状C1q受体基因(gC1qR)表达的影响。方法:以胃癌、胃炎病例组织及胃癌细胞系为研究对象,采用实时定量聚合酶链反应(Real time PCR)检测gC1qR m RNA表达水平;采用Hp DNA PCR方法,对胃窦部组织标本进行Hp水平检测;流式细胞技术进行细胞凋亡的检测及transwell实验进行细胞侵袭能力的检测。结果:在40对配对组织中有33对肿瘤组织gC1qR m RNA表达低于配对的胃炎病例组织;替吉奥单药可诱导gC1qR基因表达,抑制胃癌细胞Hp感染,同时增加胃癌细胞的凋亡率及降低胃癌细胞侵袭能力。结论:替吉奥单药诱导gC1qR基因表达,影响Hp对胃癌发生发展,是治疗胃癌的首选药物。
文摘目的:研究程序性死亡蛋白-1(programmed death protein-1,PD-1)抑制剂(信迪利单抗)联合TS方案(紫杉醇+替吉奥)治疗进展期胃癌腹膜腔转移患者的临床效果及安全性。方法:回顾性分析2019年8月—2021年12月本院收治的80例进展期胃癌腹膜腔转移患者的临床资料,将其根据治疗方式分为对照组和观察组,每组各40例。对照组采用TS方案治疗,观察组患者在对照组的基础上再给予PD-1抑制剂治疗。比较两组患者的临床疗效、治疗前后肿瘤标志物[糖类抗原(CA199)、癌胚抗原(CEA)]水平。观察治疗前、治疗1、2个疗程后的病灶直径水平,对比两组患者治疗期间的不良反应发生情况。治疗结束后对两组患者随访1年,观察随访期间的生存情况。结果:观察组总有效率高于对照组(87.50%vs 65.00%,P<0.05)。治疗后,两组患者的血清CA199、CEA水平均低于治疗前(P<0.05),且观察组患者的血清CA199、CEA水平低于对照组(P<0.05)。与治疗前比较,治疗1、2个疗程后两组患者的病灶直径水平均降低(P<0.05),观察组患者治疗1、2个疗程后病灶直径水平低于对照组(P<0.05)。观察组患者的胃肠道反应、白细胞减少、贫血、甲状腺功能减退、手足综合征等不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。观察组患者的生存率高于对照组(55.00%vs 30.00%,P=0.024)。结论:PD-1抑制剂联合TS方案可明显提高进展期胃癌腹膜腔转移患者的临床疗效,下调肿瘤标志物水平,缩小病灶,更有利于提高的患者生存率且安全性佳。
